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Abstract
Background and Aims: The immune system is likely to play a key role in the etiology of gliomas. Genetic polymorphisms in
the mannose-binding lectin gene, a key activator in the lectin complement pathway, have been associated with risk of
several cancers.
Methods: To examine the role of the lectin complement pathway, we combined data from prospectively collected cohorts
with available DNA specimens. Using a nested case-control design, we genotyped 85 single nucleotide polymorphisms
(SNPs) in 9 genes in the lectin complement pathway and 3 additional SNPs in MBL2 were tested post hoc). Initial SNPs were
selected using tagging SNPs for haplotypes; the second group of SNPs for MBL2 was selected based on functional SNPs
related to phenotype. Associations were examined using logistic regression analysis. All statistical tests were two-sided.
Nominal p-values are presented and are not corrected for multiple comparisons.
Results: A total of 143 glioma cases and 419 controls were available for this analysis. Statistically significant associations
were observed for two SNPs in the mannose-binding lectin 2 (ML2) gene and risk of glioma (rs1982266 and rs1800450, test
for trend p=0.003 and p=0.04, respectively, using the additive model). One of these SNPs, rs1800450, was associated with
a 58% increase in glioma risk among those carrying one or two mutated alleles (odds ratio=1.58, 95% confidence
interval=0.99–2.54), compared to those homozygous for the wild type allele.
Conclusions: Overall, our findings suggest that MBL may play a role in the etiology of glioma. Future studies are needed to
confirm these findings which may be due to chance, and if reproduced, to determine mechanisms that link glioma
pathogenesis with the MBL complement pathway.
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Introduction
Gliomas comprise 32% of all brain tumors and 80% of all
malignant brain tumors [1] and encompass a spectrum of
histologies that include low grade gliomas, anaplasic astrocytomas
and glioblastomas (GBM). Fewer than 4.5% of patients diagnosed
with GBMs, the most common glioma subtype (60%), are alive
five years post-diagnosis [1]. There are no established environ-
mental risk factors for gliomas other than ionizing radiation [2].
Several rare genetic syndromes, such as neurofibromatosis type I
(NF1) increase the risk of brain tumors, and several genetic regions
have been identified in genome-wide association studies (GWAS)
to be related to risk of glioma [3,4,5]. However, while necessary
when conducting agnostic analyses, over correcting for multiple
comparisons can result in missed genetic associations that are
etiologically important. This is particularly true in candidate gene
analyses, where SNPs are selected in specific genes and prior
probability for associations is hard to estimate, but in any event is
higher than when using unselected polymorphisms.
Candidate-gene approaches can be used to interrogate the role
of genetic variations in hypothesized etiologic pathways. The
complement pathway has recently been identified as playing a role
in oncogenesis [6]. Mannose-binding lectin 2 gene (MBL2), which
is located on chromosome 10 and codes for a 32-kDa plasma
glycoprotein, is involved in the innate immune response [7].
MBL2 binds to sugars on pathogens, leading to their destruction
by opsonisation through the activation of the lectin complement
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debris into macrophages [8,9]. Individuals with low functional
levels of MBL are more susceptible to bacteria, viral, and fungal
infections [7]. A number of polymorphisms in MBL2 have been
associated with MBL serum level [7]. The first polymorphism
discovered was a point mutation in codon 54 of exon 1 (rs1800450)
which results in an amino acid exchange (glycine is replaced by
aspartic acid due to a missense mutation) and in low serum levels
of MBL [10]. Subsequently, numerous additional SNPs have been
identified that influence serum levels and different haplotypes
(often described as ‘secretor’ haplotypes) have been directly linked
to serum levels [7,11].
To date, five studies have examined the association between
MBL2 polymorphisms and risk of cancer, including breast cancer
[12], stomach cancer [13,14], colon cancer [15] and cervical
cancer [16]. In these studies, MBL2 polymorphisms resulting in
lower serum levels have been associated with higher risk of cancer.
In contrast, a study of lung cancer reported improved survival with
the polymorphisms predicting low serum MBL levels [17]. No
associations were reported with the MBL2 gene and colon cancer
survival [18].
SNPs in MBL2 and the complement pathway have not been
examined in relation to risk of glioma. Thus, we examined genes in
this pathway using a candidate-gene approach and by pooling data
from three prospective cohort studies.
Methods
Ethics Statement
This investigation was approved by the Institutional Review
Board the Brigham and Women’s Hospital and/or the Harvard
School of Public Health. All participants provided informed
written consent.
Study Populations
We identified cases and controls from three large US pro-
spective cohort studies: the Physicians’ Health Study (PHS) [19],
the Nurses’ Health Study (NHS) [20], and the Health Professionals
Follow-up Study (HPFS) [21]. In brief, the PHS, a randomized
controlled trial of 22,071 male physicians, aged 40–84 years, was
initiated in 1982 to assess the efficacy of aspirin in reducing
cardiovascular disease mortality and the efficacy of beta-carotene
in reducing overall cancer incidence; the trial ended and is
currently followed as an observational cohort. The NHS, initiated
in 1976, is a prospective study of 121,700 female US registered
nurses, aged 30–55 years examining risk factors for cancer,
cardiovascular disease, and diabetes. The HPFS includes 51,529
US male health professionals, aged 40–75 years, who were
recruited in 1986 and have been followed over time to examine
lifestyle and dietary associations with major disease outcomes. As
cases and controls were selected from the same base population as
defined by the cohorts, the potential for population stratification is
limited. A number of GWAS studies have been carried out in
nested case-control studies from these cohorts, all showing little to
no population stratification [22,23]. Moreover, we restricted our
analyses to self-reported Caucasian individuals to reduce potential
population stratification.
Blood Collection
Blood samples were collected from 14,916 PHS participants
as part of the initial trial, by sending venipuncture kits to the
22,071 participants (return rate 68%) between August 1982 and
December 1984. Samples were centrifuged, aliquoted, and
stored in liquid nitrogen freezers at 280uC as either whole
blood or plasma. For the NHS, blood samples were collected
from 32,826 cohort subjects from May 1989 through September
1990. Blood collection kits were sent to 59,923 nurses who had
indicated that they would be willing to send a blood sample.
Upon arrival in the laboratory, the blood samples were
centrifuged, and the samples were divided into eight aliquots
and stored in liquid nitrogen freezers. In 1993 and 1994, blood
specimens were collected from men in HPFS. A venipuncture
kit was sent to all men who agreed to provide blood, 18,225 of
whom returned the specimens on ice using an overnight courier.
Multiple aliquots of plasma, buffy coat for DNA analyses, and
red cells were stored in liquid nitrogen freezers for use in future
assays.
Case Ascertainment and Control Selection
Cancers are reported by participants in annual (PHS) or
biennial (HFPS and NHS) follow-up questionnaires. Medical
records and pathology reports were obtained from hospitals after
permission was received from subjects or for deceased cases
identified through the National Death Index (NDI) or other
sources from next-of-kin. Deaths are usually reported by family
members or by the postal service in response to mailed
questionnaires. In addition, the NDI was searched biennially for
non-respondents, and this method has been shown to have
a sensitivity of 98% [24]. Approximately 88% of potential case
subjects (self-reported or deceased cases with glioma) were
subsequently confirmed with medical, pathology, cancer registry
data or death certificate. For the present analysis, we included
cases with any type of glioma brain tumor: astrocytoma,
glioblastoma, oligodendroglioma, ependymoma, and mixed glio-
ma subtypes.
All confirmed incident glioma cases, which provided blood
samples at baseline, were selected for this study. For each case,
three control subjects were identified among the cohort
participants who returned blood samples, who did not have
cancer, and who were alive at the time the matched case was
diagnosed. Controls were chosen at random and matched with
each case on year of birth, cohort (which automatically matches
the sex, because each cohort consists of either men only or
women only), month of blood sample collection, and race
background. In the PHS cohort, controls were also matched to
each case based on their randomly-assigned intervention group.
Candidate Gene and SNP Selection
DNA extractions were completed at the Channing Laboratory
(Boston, MA) and shipped to Imperial College in London where
a custom Illumina assay chip (Illumina, Inc., San Diego, CA) was
designed to amplify 384 SNPs distributed among approximately
40 genes. Most of the genes included in the assay were chosen
because they have either been associated with allergy and atopy.
In addition to the allergy genes, we included SNPs on 9 genes in
the complement pathway (total 85 SNPs) [6]; gene (number of
SNPs tested): C1QA (4), C1QB (7), C1QC (3), C2 (2), C3 (23), C5
(23), C5AR1 (3), CFB (10), and MBL2 (7). Three additional
functional SNPs in MBL2 were selected and tested post-hoc (see
below). For each gene, we chose a partially redundant set of
haplotype tagging SNPs, using the HapMap data phaseIII/Rel #2
for the CEU population. Partial redundancy was used to protect
against information loss in case one haplotype tagging SNP failed
to amplify. The CEU population was chosen as the reference
population for SNP tagging as the subjects in this study were
Caucasians.
Mannose-Binding Lectin 2 Gene and Glioma Risk
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DNA was obtained from all patients, and DNA concentrations
were checked using Quant-iT
TM PicoGreenH dsDNA reagent
(Invitrogen, Carlsbad, CA) and normalized to 50 ng/ml before
genotyping. A total of 250 ng DNA was used for the Illumina
GoldenGate Assay (Illumina, Inc., San Diego, CA), which was
performed according to the manufacturer’s standard three-day
protocol. Each genotyping plate was prepared with both cases and
controls to avoid plate-specific bias. Illumina clustering was
performed on the raw data using Illumina’s Genome Studio
software version 2009.1. All 384 SNPs were also manually
inspected to make sure the clusters were correctly called after
sorting via a statistical score called Gentrain. This score varies
from 1 to 0 and is based on the shape of the clusters and their
relative distance to each other. The clusters were manually called
for SNPs that were not correctly called by the software. All SNPs
that could not be called (due to overlapping clusters, more than
three clusters, or low intensity) were zeroed and excluded (n=16,
4.2%). At least one replicate was included per plate for internal
quality control, giving a total of 9 replicates across plates. The
reproducibility frequency for the 368 SNPs (after removing the
SNPs that could not be called) genotyped was 99.8%. A total of 5
HapMap Trios were also used as internal quality controls, and the
data gave an overall parent-parent-child heritability percentage of
99.6%. Individuals with call rate of ,75% (n=20) were excluded.
In the overall Illumina plate results, we observed strong
associations for SNPs previously associated with glioma (i.e., SNPs
in genes TERT, RTEL1 and PHLDB1, included on plate to serve
as controls). In addition, we observed strong associations for three
MBL2 SNPs (rs1982266, rs4935047, rs10824793; which are in
high LD). However, after reviewing the literature, we discovered
that our selected tagging SNPs in MLB2 did not include key SNPs
that contributed to the well-studied secretor MLB2 haplotype to
provide information on serum levels of MLB2. Thus, we
genotyped 5 additional SNPs (rs1800450, rs1800451, rs5030737,
rs7096206, rs11003125) using TaqMan (Applied Biosystems)
according to manufacturer’s instructions. The following Applied
Biosystem’s assay IDs were used to order four of the SNP assays:
rs1800450, assay ID: C_2336609_20; rs7096206, assay ID:
C_27858274_10; rs1800451, assay ID: C_2336608_20;
rs5030737, assay ID: C_2336610_10. A custom assay by design
was ordered for SNP rs11003125 (Forward Primer Sequence:
GGAGTTTGCTTCCCCTTGGT, Reverse Primer Sequence:
GGGCCAACGTAGTAAGAAATTTCCA, Reporter 1 Dye:
VIC, Reporter 1 Sequence: CAAGCCTGTGTAAAAC, Re-
porter 2 Dye: FAM, Reporter 2 sequence: CAAGCCTGTC-
TAAAAC). Unfortunately, 3 of the 5 SNPs that have known
impact on MBL2 serum levels have rare alleles with MAF,0.05;
data for two of the SNPs (rs1800451 and rs5030737) were
monomorphic and could not be included in the data analyses.
Deviations of the observed genotype frequencies from the Hardy-
Weinberg equilibrium (HWE) were evaluated and all three SNPs
(rs1800450, rs7096206 and rs11003125) were in HWE (p.0.05).
Genotyping success rate for rs1800450 was 83%, rs7096206 was
97% and rs11003125 was 84%. A total of 8 replicates were used
for internal quality control assessment and showed .99%
concordance for each SNP assay.
Statistical Analyses
Departures from Hardy-Weinberg equilibrium for each SNP
were determined using a x
2 test. We used unconditional logistic
regression analyses to estimate odd ratios (OR) and corresponding
95% confidence intervals (95% CI) for individual SNPs and risk of
glioma, controlling for age and cohort (conditional models resulted
in similar OR estimates). Associations were evaluated using co-
dominant models unless the minor allele frequency was less than
0.05 in controls (in which case the dominant model was used). Test
for trends were estimated using the Cochran-Armitage test.
Haplotype analyses were constructed for MBL2 using 10 SNPs
in two blocks previously identified using HapMap and including
the SNPs that were identified from the literature post-hoc. The
haplotype-specific odds ratios were estimated from genotype data
on unrelated cases and controls using unconditional logistic
regression. We used an ‘‘expectation substitution’’ approach
[25,26], which treats expected haplotype scores (calculated under
a user-specified inheritance model) as observed covariates in
a standard unconditional logistic analysis. All tests of statistical
significance were two-sided, and P values less than.05 were
considered statistically significant. All analyses were performed
using SAS 9.1 (SAS Inc., Cary, NC).
Results
After filtering poor performing samples, the final analysis
included 143 cases and 419 controls. The mean age of the cases at
blood draw and time of diagnosis was 59 and 68 years, respectively
(Table 1). Controls were matched on age at blood draw, cohort
(which also matches for sex), and month of blood sample
collection.
We observed an association with a tagging SNP on MBL2
(rs1982266; OR=0.36, 95% CI=0.19–0.66 for homozygous
recessive compared to homozygous dominant, test for trend
p=0.003) and glioma risk in our preliminary analysis of SNPs
selected from HapMap that cover 10 genes in the complement
pathway. As we could not determine the secretor phenotype from
this SNP, we reviewed the literature and selected new SNP
variants that had been linked to serum MBL2 levels in prior
studies [7,11]; all SNP results for MBL2 are presented in Table 2.
SNP rs1800450 represents a structural mutation in exon 1 of
MBL2 at codon 54 (historically referred to allele as ‘‘B’’ and
resulting in an amino acid exchange from Gly to Asp); those with
missense mutation in allele B have low levels of serum MBL [7].
We observed a dose-dependent increase in risk with SNP
rs1800450 (test for trend, p=0.04). A 58% increase in risk of
glioma was observed among those carrying one or two missense
mutations in rs1800450 (odds ratio=1.58, 95% confidence
interval=0.99–2.54), compared to those homozygous for the wild
type allele.
When restricting the analysis to glioblastomas (n=98), the
association was similar for SNP rs1982266 (OR=1.56, 95%








Age at blood draw, y 143 58.9 (8.9) 419 58.6 (8.9)
Sex, males 143 66% 419 63%
Age at diagnosis, y 143 68.3 (9.3) ––
*The blood draw period of all cohorts were as follows: NHS, 1989–1990; HPFS,
1993–1994; PHS, 1982–1984. SD=standard deviation; NHS=Nurses’ Health
Study; HPFS=Health Professionals Follow-up Study; PHS=Physicians’ Health
Study; –=controls do not have an age at diagnosis as they did not develop
cancer.
doi:10.1371/journal.pone.0061117.t001
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model=0.006), but none of the remaining MBL2 SNPs were
individually significantly related to risk.
We conducted a haplotype analysis using tagging SNPs
(Table 3); while we cannot directly relate blood MBL phenotype
to the haplotypes using our tagging SNPs, a statistically significant
association was observed for one of the haplotypes that was not
explained by any of the individual SNPs. The haplotype analysis
for glioblastoma was very similar to the overall results for glioma
risk (data not shown).
Except for the MBL2 gene, we observed no robust associations
for the complement genes included in our SNP panel (Table S1)
when testing single SNPs or haplotypes for these genes. Borderline
statistically significant associations were observed for two SNPs
with rare variants (allele frequency ,0.05); p-values for dominant
model=0.04 for rs36221133 (C2 gene), and 0.01 for rs4467185
(C5AR1 gene).
Discussion
In this prospective study combining data from three large
cohorts, we observed significant associations between SNPs in
MBL2 gene and risk of glioma. SNPs in other genes in the lectin
complement pathway were not related to glioma risk.
MBL levels have been associated with respiratory infections,
diarrheal disease, atopy and failure to thrive during infancy [7,11].
Several polymorphisms in the MBL2 gene have been linked to
serum MBL and these have been widely studied [11]. Point
mutations in codon 54 (allele B), codon 57 (allele C), and codon 52
(allele D) of exon 1 of the MBL2 gene result in very low serum
levels of MBL (for homozygous or heterozygous alleles B and C,
and to a lesser degree with allele D) [11]. Other polymorphisms
have been associated with MBL serum levels and together these
SNPs form haplotypes that explain variations in MBL serum levels
[11].
In this study, a mutation in codon 54 (rs1800450) was associated
with a higher risk of glioma which might suggest that low serum
MBL levels may increase risk of glioma. Another SNP (rs1982266)
in the MBL2 gene was strongly associated with risk; this SNP has
not been previously studied and is not in strong LD (R
2=0.125)
with the codon 54 mutation. More studies are needed to evaluate
how variants of rs1982266 may influence serum MBL levels in
order to determine if, and how, MBL2 serum levels are associated
with glioma risk.
To date, several studies have examined the relationship between
polymorphisms in the MBL2 gene and cancer risk. In one study on
gastric cancer, a strong increase in risk was observed with exon 1
allele D of MBL2 gene (haplotype analysis for HYD, compared to
HYA: OR=1.9, 95% CI=1.1–3.2), although no associations
Table 2. Association between MBL2 SNPs and risk of glioma
in 3 prospective cohort studies.
SNP Cases Controls OR
a 95% CI P
n( % ) n( % )
rs10824792
AA 40 (28.8) 139 (34.1) 1.0 ref.
AG 73 (52.5) 195 (47.8) 1.30 (0.83–2.02)
GG 26 (18.7) 74 (18.1) 1.22 (0.70–2.16) 0.39
rs11595876
AA 120 (86.3) 372 (90.5) 1.0 ref.
AG 18 (12.9) 35 (8.5) 1.60 (0.87–2.92)
GG 1 (0.7) 0. 4 (1.0) 0.73 (0.08–6.65) 0.26
rs930508
CC 94 (68.1) 262 (63.7) 1.0 ref.
CG 40 (29.0) 132 (32.1) 0.86 (0.56–1.32)
GG 4 (2.9) 17 (4.1) 0.65 (0.21–1.98) 0.34
rs1838066
AA 50 (35.7) 176 (42.8) 1.0 ref.
AG 72 (51.4) 175 (42.6) 1.45 (0.95–2.20)
GG 18 (12.9) 60 (14.6) 1.05 (0.57–1.95) 0.43
rs1982266
b
GG 53 (37.9) 113 (27.8) 1.0 ref.
GA 70 (50.0) 193 (47.2) 0.78 (0.51–1.20)
AA 17 (12.1) 102 (25.1) 0.36 (0.20–0.66) 0.003
rs1800450
c
CC 81 (69.8) 271 (78.6) 1.0 ref.
CT 32 (27.6) 71 (20.6) 1.51 (0.93–2.45)
TT 3 (2.6) 3 (0.9) 3.44 (0.68–17.4) 0.04
rs7096206
d
CC 86 (61.9) 238 (59.5) 1.0 ref.
CG 47 (33.8) 139 (34.8) 0.95 (0.63–1.44)
GG 6 (4.3) 23 (5.8) 0.74 (0.29–1.88) 0.58
rs11003125
e
CC 50 (41.3) 146 (42.0) 1.0 ref.
CG 55 (45.5) 146 (42.0) 1.09 (0.70–1.71)
GG 16 (13.2) 56 (16.1) 0.82 (0.43–1.56) 0.72
aOdds ratio adjusted for age and study (cohort; sex).
brs4935047 and rs10824793 are in complete LD with rs1982266 and thus results
are not shown.
cAlso known as Ex1-27G.A; A/B.
dAlso known as 2289 G.C; X/Y.
eAlso known as 2618 G.A; H/L.
doi:10.1371/journal.pone.0061117.t002
Table 3. MBL2 haplotypes associated with risk of glioma in 3
prospective studies.
Haplotype
a Cases Controls OR
b 95% CI
AACGAGGCCG 75.9(26.9%) 238.44 (28.7%) 1.0 Ref.
AACAGAACCC 42.9 (15.2%) 155.5 (18.7%) 0.87 0.58–1.32
GAGAGAACGC 46.4 (16.5%) 140.2 (16.9%) 1.04 0.68–1.59
GACAAGGTCC 29.3 (10.4%) 86.0 (10.3%) 1.01 0.61–1.67
AGCGAGGCCG 16.5 (5.8%) 41.4 (5.0%) 1.24 0.68–2.28
GACAAGGCCC 18.4 (6.5%) 30.0 (3.6%) 2.10 1.05–4.19
GACAGAACGC 12.0 (4.3%) 31.5 (3.8%) 1.27 0.60–2.67
GACAGAACCC 10.9 (3.9%) 31.6 (3.8%) 1.06 0.50–2.27
AACGAGGCCC 7.1 (2.5%) 16.7 (2.0%) 1.36 0.49–3.79
AACAAGGTCC 5.4 (1.9%) 11.1 (1.3%) 1.82 0.55–6.08
P of LRT test=0.30.
P for global test=0.66.
aHaplotype defined as (in this order): rs10824792; rs11595876; rs930508;
rs1838066; rs10824793; rs4935047;rs1982266; rs1800450; rs7096206;
rs11003125.
bAdjusted for age and study (cohort; sex).
doi:10.1371/journal.pone.0061117.t003
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cancer, no overall association was observed with the MBL2 gene,
although only codon 54 was measured [14], and this SNP was not
associated with stomach cancer in the study by Baccarelli et al
[13]. In a recent study examining a large number of SNPs in the
MBL2 gene, including SNPs in the 39UTR region, haplotypes
associated with low MBL serum levels were associated with
elevated risk of colon cancer in African-Americans but not
Caucasians [15]. Similar associations were also noted between
MBL2 haplotypes and breast cancer risk among African-American
women, but not Caucasians [12].
There has also been interest to determine whether MBL2
polymorphisms can influence rates of viral infections related to
cancer, including human papillomavirus (HPV) infection [16,27],
hepatitis C virus [28] and BK virus coinfection in HPV-positive
cervical lesions [29]. These studies have reported mixed results.
The impact of MBL serum levels on cancer risk might be
directly linked to its ability to bind apoptotic or necrotic cells and
facilitate macrophage uptake without activating the complement
pathway; recent in vitro studies show that MBL may act in-
dependently of the complement cascade by facilitating the
ingestion of apoptotic cells by human macrophages through
macropinocytosis [8,30]. The role of the immune response and
inflammatory response in relation to carcinogenesis is complex
[31] and the role of MBL on cancer risk requires further study.
A limitation of our study is the small sample size, despite pooling
data from 3 large cohort studies; future studies will have to
reproduce our findings. Another limitation is the genotype failure
for SNP rs1800451 (allele C); data on this SNP might have
provided more information on genetic variation that affect serum
levels of MBL. We did not directly measure MBL levels in plasma
(as it was not part of the original aims of the funded cohort study),
accordingly we could not directly examine the relation between
haplotypes and MBL serum levels; however, the literature on the
relation between the polymorphisms in this gene and associated
phenotypes is well documented [7,11].
To our knowledge, this is the first study to examine MBL2
polymorphisms and risk of glioma. We observed a strong
association between two MBL2 polymorphisms which are not in
high linkage disequilibrium and risk of glioma. While our results
will need to be confirmed in a larger sample, they may provide
a novel and exciting area for future research on glioma
pathogenesis. The role of the immune system in glioma etiology
is critical, as demonstrated by the numerous consistent findings for
allergies and IgE [32], and needs further elucidation.
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